MARKET

ILMN

ILMN

Illumina
NASDAQ

Real-time Quotes | Nasdaq Last Sale

438.00
-9.01
-2.02%
After Hours: 437.05 -0.95 -0.22% 18:02 09/20 EDT
OPEN
440.67
PREV CLOSE
447.01
HIGH
449.99
LOW
433.00
VOLUME
920.35K
TURNOVER
--
52 WEEK HIGH
555.77
52 WEEK LOW
260.42
MARKET CAP
64.25B
P/E (TTM)
84.16
1D
5D
1M
3M
1Y
5Y
Illumina says it had expected EU hold order on Grail
reuters.com · 5h ago
UPDATE 2-Illumina expects EU order to keep Grail a separate company
reuters.com · 8h ago
UPDATE 1-Illumina faces EU interim measures after gun-jumping Grail deal
reuters.com · 8h ago
BRIEF-Illumina Says Reaffirms Commitment To National Project Of Bio Big Data In Korea
reuters.com · 22h ago
Illumina reaffirms commitment to the National Project of Bio Big Data in Korea
Illumina, Inc. (NASDAQ: ILMN) today announced that the National Project of Bio Big Data in Korea has selected Illumina technology for the second pilot project in their effort to work towards establishing a national digital library on health and genome data...
PR Newswire · 1d ago
Research Alert: CFRA Lowers View On Shares Of Illumina, Inc. To Hold From Buy
MT Newswires · 4d ago
Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team
CAMBRIDGE, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale ...
GlobeNewswire · 4d ago
BRIEF-Illumina Accelerator Invests In Seven Genomics Startups For Third Global Cycle
reuters.com · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ILMN. Analyze the recent business situations of Illumina through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ILMN stock price target is 459.00 with a high estimate of 555.00 and a low estimate of 350.00.
EPS
Institutional Holdings
Institutions: 1.37K
Institutional Holdings: 138.64M
% Owned: 94.51%
Shares Outstanding: 146.70M
TypeInstitutionsShares
Increased
396
4.32M
New
129
1.15M
Decreased
350
5.22M
Sold Out
95
556.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.76%
Healthcare Equipment & Supplies
-1.59%
Key Executives
Non-Executive Chairman/Independent Director
John Thompson
President/Chief Executive Officer/Director
Francis deSouza
Chief Financial Officer
Sam Samad
Chief Operating Officer
Robert Ragusa
Chief Human Resource Officer
Aimee Hoyt
Senior Vice President
Joydeep Goswami
Chief Technology Officer
Alex Aravanis
Chief Accounting Officer/Vice President
Jose Torres
Chief Marketing Officer
Kathryne Reeves
General Counsel/Secretary
Charles Dadswell
Other
Phillip Febbo
Other
Susan Tousi
Independent Director
Frances Arnold
Independent Director
Caroline Dorsa
Independent Director
Robert Epstein
Independent Director
Scott Gottlieb
Independent Director
Gary Guthart
Independent Director
Philip Schiller
Independent Director
Susan Siegel
No Data
About ILMN
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

Webull offers kinds of Illumina, Inc. stock information, including NASDAQ:ILMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ILMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ILMN stock methods without spending real money on the virtual paper trading platform.